Silence Therapeutics plc Share Price
Stocks
SLN
US82686Q1013
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
01:30:00 29/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 19.71 USD | -0.35% |
|
+0.20% | +224.18% |
| 20/10 | Health Care Up on Deal Activity - Health Care Roundup | DJ |
| 20/10 | Silence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares Surge | MT |
| Market Cap | 89Cr 118.67Cr 106.47Cr 98Cr 166.56Cr 11TCr 168.57Cr 1.18TCr 468.79Cr 5.91TCr 445.33Cr 435.93Cr 19TCr | P/E 2026 * |
-38.6x | P/E 2027 * | -31.8x |
|---|---|---|---|---|---|
| Enterprise Value | 76Cr 100.79Cr 90Cr 84Cr 141.46Cr 9.6TCr 143.17Cr 999.56Cr 398.13Cr 5.02TCr 378.21Cr 370.22Cr 16TCr | EV / Sales 2026 * |
2,303x | EV / Sales 2027 * | 941x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SLN | Delayed | |
CBOE
| SLN | Real-time | |
|
Tradegate
| XRP2 | Real-time | |
|
Boerse Muenchen
| XRP2 | Real-time | |
|
Deutsche Boerse AG
| XRP2 | Delayed | |
|
Börse Stuttgart
| XRP2 | Delayed |
Last Transcript: Silence Therapeutics plc
| 1 day | -0.35% | ||
| 1 week | +0.20% | ||
| Current month | +80.33% | ||
| 1 month | +75.98% | ||
| 3 months | +70.65% | ||
| 6 months | +155.97% | ||
| Current year | +224.18% |
| 1 week | 19.65 |  | 19.86 |
| 1 month | 8.66 | | 19.86 |
| Current year | 4.19 | | 19.86 |
| 1 year | 4.19 | | 19.86 |
| 3 years | 1.97 | | 27.72 |
| 5 years | 1.97 | | 27.72 |
| 10 years | 1.97 | | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 01/12/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 01/02/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 21/06/2018 |
Iain Ross
CHM | Chairman | 72 | 01/01/2004 |
Tim McInerney
BRD | Director/Board Member | 65 | 05/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/07/26 | Sell | 8,65,112 | 0.6105% | |||
| 02/01/26 | Free | Chief Financial Officer | 3,75,000 | 0.2646% | ||
| 02/01/26 | Free | Director | 90,000 | 0.0635% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.35% | +0.20% | +169.63% | +176.83% | 118.67Cr | |
| +0.65% | -3.36% | +36.98% | +60.50% | 6.41TCr | |
| +1.76% | +1.27% | +11.82% | +81.21% | 5.55TCr | |
| -0.94% | +0.99% | +10.45% | +100.19% | 5.3TCr | |
| +2.76% | +0.87% | +27.92% | +55.07% | 4.6TCr | |
| +2.00% | -3.39% | +17.83% | +119.04% | 4.25TCr | |
| +1.34% | -2.86% | +224.43% | +914.08% | 4.04TCr | |
| +0.64% | -3.95% | +11.15% | +45.57% | 3.23TCr | |
| +29.06% | +47.63% | +107.12% | +92.73% | 3.45TCr | |
| -2.98% | -0.62% | +22.96% | -10.93% | 2.42TCr | |
| Average | +3.40% | +3.69% | +64.03% | +163.43% | 3.94TCr | |
| Weighted average by Cap. | +3.32% | +3.48% | +49.56% | +159.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 4L 4L 4L 6L 4.17Cr 6L 43.4L 17.29L 2.18Cr 16.42L 16.08L 6.92Cr | 8L 10.12L 9L 8L 14.21L 9.64Cr 14.38L 1Cr 39.99L 5.04Cr 37.99L 37.18L 16Cr |
| Net income | -4.26Cr -5.67Cr -5.08Cr -4.7Cr -7.95Cr -539.72Cr -8.05Cr -56Cr -22Cr -282.43Cr -21Cr -21Cr -896.6Cr | -6.49Cr -8.63Cr -7.75Cr -7.16Cr -12Cr -822.23Cr -12Cr -86Cr -34Cr -430.26Cr -32Cr -32Cr -1.37TCr |
| Net Debt | -13Cr -18Cr -16Cr -15Cr -25Cr -1.7TCr -25Cr -177.4Cr -71Cr -891.47Cr -67Cr -66Cr -2.83TCr | -18Cr -23Cr -21Cr -19Cr -33Cr -2.23TCr -33Cr -232.06Cr -92Cr -1.17TCr -88Cr -86Cr -3.7TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/26/28 | $19.71 | -0.35% | 27,57,826 |
| 27/26/27 | $19.78 | 0.00% | 14,88,216 |
| 26/26/26 | $19.78 | +0.56% | 46,54,224 |
| 23/26/23 | $19.67 | +0.05% | 21,26,186 |
| 22/26/22 | $19.66 | -0.05% | 30,78,639 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SLN Stock
Select your edition
All financial news and data tailored to specific country editions
